Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Kyobu Geka ; 62(10): 896-9, 2009 Sep.
Article in Japanese | MEDLINE | ID: mdl-19764497

ABSTRACT

We report a case of pneumothorax and abdominal free air after percutaneous tracheostomy (PCT). A 80-year-old female was intubation for upper respiratory stenosis. We thought tracheal stenosis recurrence after extubation. PCT was performed. Respiratory insufficiency and subcutaneous emphysema appeared rapidly at face, neck and precordia Subcutaneous emphysema was pushed away. PCT was performed once more. Chest X-ray showed pneumothorax in right thoracic cavity. Thoracostomy tube was intubation. Chest computed tomography (CT) scan showed pneumothorax another thoracic cavity and abdominal free air. Vital signs was not worse, so observation. Postoperative course was uneventful. The patient was recovered. We thought that PCT was effective under bronchofiber.


Subject(s)
Pneumothorax/etiology , Tracheostomy/methods , Abdomen , Aged, 80 and over , Air , Female , Humans , Postoperative Complications
2.
Oncol Rep ; 7(5): 1107-12, 2000.
Article in English | MEDLINE | ID: mdl-10948347

ABSTRACT

This retrospective study was conducted to determine the indication of chest wall irradiation following mastectomy in axillary node-positive breast cancer patients. Between 1982 and 1993, 103 women with axillary node-positive breast cancer received postoperative radiation therapy following mastectomy using the hockey-stick field, which included the ipsilateral supraclavicular fossa and internal mammary nodes, without the chest wall. Ages ranged from 33 to 73 years (median: 47). Thirty-five patients underwent modified radical mastectomy, 48 radical mastectomy, and 20 extended radical mastectomy. Twenty-two patients had 1-3 positive axillary nodes, and 81 had 4 or more positive axillary nodes. The total doses ranged from 42 to 64 Gy (median 54 Gy) with a daily fraction size of 2 Gy. Adjuvant chemotherapy was given to 75 patients, and hormone therapy was administered to 78 patients. The median follow-up time was 121 months (range, 68-191 months) for the 57 surviving patients. The actuarial overall survival rate and the chest wall control rate at 10 years for all patients were 55% and 85%, respectively. Of the 103 patients, 14 developed chest wall recurrence. In the analysis, status of vascular invasion alone had a significant impact on chest wall control. In patients with definite vascular invasion, 2 of 5 (40%) patients with 1 to 3 positive axillary nodes, and 10 of 31 (32%) with 4 or more positive axillary nodes developed chest wall recurrence. In contrast, no patients without definite vascular invasion developed chest wall recurrence. Factors such as age, menopausal status, pathology, tumor location, extent of resection, estrogen receptor status, total dose, chemotherapy, and hormone therapy did not influence the development of chest wall recurrence. Among node-positive breast cancer patients following mastectomy, those with definite vascular invasion should be delivered chest wall irradiation regardless of the number of positive axillary nodes. In contrast, those without definite vascular invasion need not be administered chest wall irradiation.


Subject(s)
Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Adult , Aged , Axilla , Breast Neoplasms/pathology , Disease-Free Survival , Female , Humans , Lymphatic Metastasis , Mastectomy/methods , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Radiation Injuries/etiology , Radiation Pneumonitis/etiology , Radiotherapy, Adjuvant/adverse effects , Retrospective Studies , Survival Analysis , Thorax/radiation effects , Treatment Outcome
3.
Breast Cancer Res Treat ; 53(1): 33-9, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10206070

ABSTRACT

To determine the incidence of microsatellite instability (MSI) and its relationship with both clinicopathologic parameters and patient survival, 101 cases of breast cancer were investigated. In addition, transforming growth factor-beta (TGF-beta) receptor type II (RII) gene mutation was also examined to clarify the relation to MSI in breast cancer development. MSI and RII gene mutation were screened by single strand conformation polymorphism (SSCP). The mutations of the RII gene were confirmed by a direct sequence. An association between the MSI status and the clinicopathological features was examined to assess the potential of the MSI status as a prognostic indicator in sporadic breast cancer cases. MSI was detected in 12 of 101 (11.9%) breast cancer cases. The positive MSI breast cancer cases showed relatively more advanced disease than negative MSI cases, and also exhibited relatively poorer prognoses. No RII gene mutations were observed in any of the breast cancer cases. Our data suggest that the MSI status may thus be a useful indicator for the prognosis of sporadic breast cancer cases. However, the breast seems to be an infrequent target organ for cancer development through RII gene mutations. As a result, tumor progression through this pathway appears to be related to organ specificity. For positive MSI breast cancers, other target genes therefore still need to be identified.


Subject(s)
Breast Neoplasms/genetics , Breast Neoplasms/pathology , Microsatellite Repeats , Receptors, Transforming Growth Factor beta/genetics , Breast Neoplasms/mortality , DNA Primers , DNA, Neoplasm/chemistry , Female , Humans , Middle Aged , Mutation , Polymerase Chain Reaction , Polymorphism, Single-Stranded Conformational
7.
Hepatogastroenterology ; 45(21): 882-4, 1998.
Article in English | MEDLINE | ID: mdl-9684151

ABSTRACT

Advanced cancer of the pancreatic head, especially in its caudal portion, has a limited surgical resectability due to its frequent invasion to the superior mesenteric vein (SMV). A patient with advanced carcinoma of the pancreatic head with vascular invasion to the major bifurcation of the SMV, underwent a pancreatico-duodenectomy under a two-step passive bypass of the portal flow. The marginal colic veins were dilated and formed a long collateral route to the inferior mesenteric vein and the splenic vein due to stenosis of the SMV. The venous flow in this vein was then easily interrupted with the surgical manipulation of the transverse colon. The first passive bypass was thus inserted into the accessory right colic vein to preserve the venous return from both the small intestine and the colon, and also to enable surgical dissection of the invaded SMV itself. After a thorough dissection of the invaded SMV, a second bypass was inserted into the main trunk of the SMV through the dissected vascular stump. Subsequently the passive bypass was maintained until the portal reconstruction with an interposition of the left common iliac vein could be performed. The patient recovered well from the surgery without any complications throughout the postoperative course. In summary, the two-step portal bypass describes, is thus considered a stable and safe procedure for the reconstruction of the superior mesenteric vein, during pancreatoduodenectomy for advanced carcinoma of the pancreatic head.


Subject(s)
Mesenteric Veins/surgery , Pancreatic Neoplasms/surgery , Plastic Surgery Procedures/methods , Portal Vein/surgery , Angiography , Humans , Male , Middle Aged , Pancreatic Neoplasms/diagnostic imaging , Tomography, X-Ray Computed
8.
Breast Cancer ; 5(2): 205-208, 1998 Apr 25.
Article in English | MEDLINE | ID: mdl-11091650

ABSTRACT

A huge phyllodes tumor of the breast that appeared grossly malignant in a 43-year-old woman is described. The patient suffered from a large breast tumor thatsuddenly increased in size over 5 months to occupy the entire breast. The tumorwas hard, ulcerated and 20 cm in greatest diameter. Diagnostic imaging(US, CT and MRI)demonstrated a circumscribed mass with a large cystic cavity. She underwent total mastectomy under a diagnosis of malignant breast tumor. Grossly, the cut surface of the tumor showed a large cystic cavity surrounding a fleshy, hemorrhagic and necrotic mass with a lobulared or trabeculared appearance. Unexpectedly, benign phyllodes tumor(PT)without any stromal overgrowth was diagnosed histologically. She has been doing well since total mastectomy. In our case and in many other reported cases, PT does not show any distinctive correlation between pathologic findings and tumor behavior. Thus wide local excision is the preferred initial treatment for PT.

9.
J Surg Res ; 69(2): 429-34, 1997 May.
Article in English | MEDLINE | ID: mdl-9224419

ABSTRACT

Plasma L-arginine is usually deficient immediately after hepatic reperfusion in orthotopic liver transplantation, which may also contribute to the occurrence of either hepatic ischemia-reperfusion injury or pulmonary hypertension. In this study, exogenous L-arginine was thus experimentally used to reverse the deficient status of the L-arginine/NO pathway. An in vivo model of 1 hr hepatic ischemia and reperfusion was thus tested in both rats (Experiment A) and pigs (Experiment B). In Experiment A, 10 mg/kg of L-arginine (group 1, n = 7), D-arginine (group 2, n = 7), or saline (group 3, n = 7) was administered through the portal vein. The hepatic tissue blood flow, at 20 min after reperfusion, improved in group 1 (70.7 +/- 7.0% of the preclamp levels) compared to groups 2 and 3. The serum glutamate oxaloacetate transaminase levels at 24 hr after reperfusion were also lower in group 1 (320 +/- 22.2 IU/L) than in either group 2 or group 3. The intrahepatic NO levels showed a temporal burst (> 15,000 pA current) after reperfusion only in group 1. In Experiment B, 10 mg/kg of L-arginine (group 4, n = 5), D-arginine (group 5, n = 5), or 10 ml of saline (group 6, n = 5) was administered through the portal vein. In group 4, the MPAP (mean pulmonary arterial pressure)/MAP (mean arterial pressure) was lower than that observed in groups 5 and 6. In conclusion, exogenous L-arginine administered from the portal vein was thus found to be effective in mitigating both portal hypertension and reperfusion injury by producing an increased amount of NO immediately after reperfusion.


Subject(s)
Arginine/pharmacology , Liver/blood supply , Reperfusion Injury/etiology , Animals , Aspartate Aminotransferases/metabolism , Blood Pressure , Citrulline/blood , Cyclic GMP/blood , Female , Hemodynamics , Male , Nitrates/metabolism , Nitric Oxide/metabolism , Nitrites/metabolism , Rats , Rats, Wistar , Swine , Time Factors
10.
Transpl Int ; 10(3): 207-11, 1997.
Article in English | MEDLINE | ID: mdl-9163861

ABSTRACT

To assess the effects of cyclosporin (CyA) on endothelin-1 (ET-1) in rat liver allograft rejection, we evaluated ET-1 expression in samples obtained from BN(RT1n)-to-BN (group 1) rats, DA(RT1a)-to-BN (group 2) rats, and DA-to-BN rats treated with 5 mg/kg per day of CyA (group 3). Serum and hepatic ET-1 levels, determined by a radioimmunoassay, remained unchanged in group 1. In group 2, the ET-1 levels peaked on postoperative day (POD) 5 in the liver at 344 +/- 31.6 pg/g wet, and on POD 7 in the serum at 38.7 +/- 13.1 pg/ml. In group 3, hepatic and renal ET-1 levels showed a progressive increase until POD 10, while serum ET-1 levels remained unchanged. In conclusion, acute rejection caused a temporary increase in the ET-1 level in both the serum and the liver in the early postoperative period what might have been caused by endothelial damage due to ongoing, acute rejection. CyA caused a time-dependent increase in the ET-1 level in both the liver and the kidney without an increase in the serum ET-1 level. The serum ET-1 level might have been affected by the clearance of ET from the liver or kidney.


Subject(s)
Cyclosporine/pharmacology , Endothelin-1/metabolism , Liver Transplantation/physiology , Animals , Cyclosporine/metabolism , Graft Survival , Immunosuppressive Agents/pharmacology , Kidney/metabolism , Liver/metabolism , Male , Radioimmunoassay , Rats , Rats, Inbred BN , Rats, Inbred Strains , Time Factors
12.
Leukemia ; 9(10): 1768-70, 1995 Oct.
Article in English | MEDLINE | ID: mdl-7564523

ABSTRACT

Adult T cell leukemia (ATL) is the T cell malignancy caused by human T lymphotropic virus type I (HTLV-I), and HTLV-I is also the causative agent of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although HTLV-I causes both diseases, concomitant occurrence is reported to be rare. This paper describes two cases of HAM/TSP that developed into lymphoma-type ATL after the onset of HAM/TSP. In one case, the same HTLV-I infected clone could be detected by polymerase chain reaction in peripheral blood obtained when the patient was diagnosed as HAM/TSP. This finding showed that the HTLV-I clone already existed at the stage of HAM/TSP. Since frequent detection of clonal proliferation of HTLV-I infected cells has been reported previously in patients with HAM/TSP, careful follow-up is needed for patients with HAM/TSP.


Subject(s)
Human T-lymphotropic virus 1/isolation & purification , Leukemia, T-Cell/virology , Paraparesis, Tropical Spastic/virology , Base Sequence , Disease Progression , Female , Human T-lymphotropic virus 1/genetics , Humans , Leukemia, T-Cell/pathology , Male , Middle Aged , Molecular Sequence Data , Paraparesis, Tropical Spastic/pathology , Polymerase Chain Reaction
13.
Surg Today ; 25(12): 1038-42, 1995.
Article in English | MEDLINE | ID: mdl-8645937

ABSTRACT

We present here in the case of a 75-year-old man who developed synchronous double cancers of the remnant stomach and pancreas 12 years after undergoing distal gastrectomy for gastric carcinoma. The patient was referred to our hospital in March, 1993, with a provisional diagnosis of carcinoma of the remnant stomach. Laboratory data on admission showed an abnormal level of CA19-9 (116.1 U/ml) and positive occult blood in the stools. An upper gastrointestinal series and gastroendoscopy demonstrated an ulcerative polypoid tumor in the gastric stump proximal to the gastroduo-denostomy anastomosis, and a biopsy confirmed the findings of mucinous adenocarcinoma. Abdominal computed tomography (CT) scan revealed a low-density nodule anterior to the abdominal aorta, suggestive of a nodal metastasis. A laparotomy was performed which also disclosed a low-density mass located within the head of the pancreas. The patient was subsequently diagnosed as having double carcinomas of the remnant stomach and pancreas, and total gastrectomy and pancreatoduodenectomy were carried out. The histologic sections from the remnant stomach showed mucinous adenocarcinoma, whereas those from the pancreas showed tubular adenocarcinoma. Double carcinomas in this association are extremely rare and this case may in fact be the first observation of synchronous double cancers of the remnant stomach and pancreas.


Subject(s)
Adenocarcinoma, Mucinous/surgery , Adenocarcinoma/surgery , Anastomosis, Surgical , Gastrectomy , Gastric Stump/surgery , Neoplasms, Multiple Primary/surgery , Pancreatic Neoplasms/surgery , Postoperative Complications/surgery , Stomach Neoplasms/surgery , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/pathology , Adenocarcinoma, Mucinous/diagnostic imaging , Adenocarcinoma, Mucinous/pathology , Aged , Gastric Stump/diagnostic imaging , Gastric Stump/pathology , Humans , Male , Neoplasm Staging , Neoplasms, Multiple Primary/diagnostic imaging , Neoplasms, Multiple Primary/pathology , Pancreatic Neoplasms/diagnostic imaging , Pancreatic Neoplasms/pathology , Pancreaticoduodenectomy , Postoperative Complications/diagnostic imaging , Postoperative Complications/pathology , Reoperation , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/pathology , Tomography, X-Ray Computed
14.
Jpn J Antibiot ; 46(1): 53-9, 1993 Jan.
Article in Japanese | MEDLINE | ID: mdl-8455331

ABSTRACT

Cefpodoxime (CPDX-PR) was evaluated clinically in respiratory tract infections. The results obtained are summarized as follows; 1. The total number of the patients who were treated with CPDX-PR was 61, out of whom 53 cases were evaluated for clinical efficacy and 55 cases were investigated for the safety of the drug. CPDX-PR was given orally twice a day at 100-200 mg for 5-21 days. 2. Clinical efficacies were excellent in 9 patients, good in 36, fair in 4 and poor in 4. The overall clinical efficacy was 84.9%. In particular, CPDX-PR showed satisfactory efficacy for acute respiratory infections and mild chronic respiratory infections, with efficacy rates of 88.6% (31/35) and 100% (8/8), respectively. 3. No adverse reactions was observed, but slight and transient elevation of BUN was noted. In conclusion, it has been confirmed that CPDX-PR is an excellent and safe drug for the treatment of the respiratory tract infections.


Subject(s)
Ceftizoxime/analogs & derivatives , Prodrugs/therapeutic use , Respiratory Tract Infections/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Bacteria/drug effects , Bacteria/isolation & purification , Ceftizoxime/administration & dosage , Ceftizoxime/therapeutic use , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Prodrugs/administration & dosage , Respiratory Tract Infections/microbiology , Cefpodoxime Proxetil
SELECTION OF CITATIONS
SEARCH DETAIL
...